Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 12, 2016. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific executive share transaction.
Material Changes
The filing reports the acquisition of ordinary shares by Sir Andrew Witty, CEO of GSK, under the Company's ShareReward Plan. There are no reported material changes to the company's financial position or operations in this document.
Transaction Details and Commentary
- Executive: Sir Andrew Witty (CEO)
- Transaction Type: Acquisition of ordinary shares (25 pence each, ISIN: GB0009252882)
- Volume: 14 total ordinary shares (7 partnership shares and 7 matching shares)
- Price: £16.7127 per share
- Date: July 11, 2016 (12:18 GMT)
- Exchange: London Stock Exchange (XLON)
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies beyond the standard transaction disclosure.
Investor Verification Points
- Verify the total number of shares held by Sir Andrew Witty following this transaction in subsequent filings.
- Confirm the terms of the ShareReward Plan to understand the matching share mechanism.
- Note that this filing does not reflect the company's quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.